Metabocore: needle biopsy assay of drug sensitivity for solid tumors
Active Cooperative Agreement Awarded Last action
- Award ID
- U01CA281433
- Recipient
-
University Of Washington UEI HD1WMN6945W6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,177,949
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 43% complete
- Place of performance
- Seattle, WA 98195, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goal of personalized oncology is to select the most appropriate drug(S) for individual cancers. A number of platforms (e.g., organoids and PDX mice) have been developed to generate human cancer models for drug sensitivity testing, but they have yet to deliver on their promise as an every-day clinical assay for use by oncologists. The major hurdles limiting success of personalized drug sensitivity testing are the long turnaround time and the amount of starting material needed, in addition to the loss of the original tumor microenvironment. To address these shortcomings, we developed an elegant assay to evaluate drug sensitivity based on metabolic changes in fresh tumor tissues obtained through needle biopsies. Our so-called metabocore assay takes advantage of an optimized organotypic culture platform that is suitable drug testing immediately upon specimen collection, and a novel single-cell metabolic assay that detects changes in metabolism of cancer cells within a short time of drug exposure. Consequently, quantitative results of relative drug sensitivity can be obtained within a week of the biopsy. In order to advance our assay towards clinical use, we need to create a robust SOP with defined parameters for each step of the assay in order to achieve reproducible results. The objectives of the proposal are to examine how biospecimen preanalytical conditions affect assay performance. Specifically, we will quantify the effects of each of the following variables on tissue viability and drug response: type and size of biopsy needles, transport solution, overnight storage, culture conditions, recovery time, drug concentration, treatment duration, and protocols for tissue dissociation. Based on these findings, we will create a SOP for metabocore and test its clinical performance in a pilot study using needle biopsies of human liver cancers.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $388,418 | |
| Amendment | $388,418 | |
| Original award | $401,113 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Institute For Systems Biology | $189,222 | |
| Institute For Systems Biology | $193,497 |
Quick answers
Who received award U01CA281433?
U01CA281433 was awarded to University Of Washington by National Cancer Institute (National Institutes of Health) on September 19, 2024.
How much is award U01CA281433 worth?
$1,177,949 has been obligated on U01CA281433.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award